Paul Saladino
Paul Saladino is a health content creator and commentator who produces material on nutrition and wellness. His work focuses on animal-based diets, lifestyle optimization, and the health effects of substances such as nicotine. No academic publications were provided in his record.
67 claims checked on air: 11 context 2 contradicted 6 overstated 40 supported 8 unverified
What they said on air - context
Sugars added to cigarettes produce acetaldehyde when burned, which inhibits dopamine breakdown.
"They added sugars that produce acetaldehyde when they burn, a compound that inhibits the breakdown of dopamine that leads to a bigger high, more addiction, and more craving." (said at 0:04:36)
The combustion of sugars and polysaccharides added to tobacco generates acetaldehyde, which can react with biogenic amines to form condensation products (such as the β-carboline harman). Harman acts as a monoamine oxidase (MAO) inhibitor, reducing the breakdown of monoamines including dopamine. Preclinical rodent studies demonstrate that acetaldehyde and MAO inhibitors can synergize with nicotine to increase reinforcement and self-administration; however, whether acetaldehyde concentrations achieved from sugar pyrolysis directly drive enhanced addiction in human smokers remains an active hypothesis largely derived from animal and chemical models.
- supports: Role of acetaldehyde in tobacco smoke addiction. (European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2007) · cited 142x in the literature
"In rodents, acetaldehyde induces reinforcing effects, and acts in concert with nicotine. Harman and salsolinol, condensation products of acetaldehyde and biogenic amines, may be responsible for the observed reinforcing effect of acetaldehyde. Harman and salsolinol inhibit monoamine oxidase (MAO), and some MAO-inhibitors are known to increase nicotine self-administration and maintain behavioural sensitization to nicotine." (abstract, passage verified)
pubmedfull study (doi) - context: Effects of MAO inhibition and a combination of minor alkaloids, β-carbolines, and acetalde… (Drug and alcohol dependence 2015) · cited 48x in the literature
"These data suggest that this cocktail of constituents does not significantly alter the primary reinforcing effects of nicotine, but constituents that inhibit MAO may increase the primary reinforcing effects of nicotine, especially at low doses." (abstract, passage verified)
pubmedfull study (doi)
Cigarette combustion produces over 7,000 chemicals, including at least 70 known carcinogens.
"When you light that cigarette, combustion produces over 7,000 chemicals. At least 70 of these are known carcinogens: formaldehyde, benzene, arsenic, carbon monoxide." (said at 0:05:05)
Established tobacco research and regulatory assessments (such as those from the US Surgeon General, CDC, and FDA) confirm that cigarette smoke contains over 7,000 chemicals, with at least 70 (and by some evaluations over 80) classified as known or probable carcinogens. Formaldehyde, benzene, and arsenic are well-established IARC Group 1 human carcinogens present in tobacco smoke. However, carbon monoxide, while a major combustion toxicant that contributes significantly to cardiovascular disease and tissue hypoxia, is a toxic gas rather than a carcinogen.
- supports: Online Information About Harmful Tobacco Constituents: A Content Analysis. (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2017) · cited 13x in the literature
"Tobacco products and smoke contain more than 7000 chemicals (ie, constituents)." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Advanced Materials Design for Adsorption of Toxic Substances in Cigarette Smoke. (Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023) · cited 58x in the literature
"Tobacco smoke is a complex mixture containing over 7000 chemical compounds, 86 of which are identified to have "sufficient evidence of carcinogenicity" in either animal or human tests. Thus, tobacco smoke poses a significant health risk to humans. This article focuses on materials that help reduce the levels of major carcinogens in cigarette smoke; these include nicotine, polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, hydrogen cyanide, carbon monoxide, and formaldehyde." (abstract, passage verified)
pubmedfull study (doi)
Over 50 studies indicate that nicotine users have a 60% lower risk of developing Parkinson's disease.
"There is over 50 studies suggesting that nicotine users have a 60% lower risk of Parkinson's." (said at 0:15:41)
The speaker's numbers closely match the extensive epidemiological literature on cigarette smoking and Parkinson's disease (PD), but conflate tobacco/cigarette smoking with pure nicotine use. A landmark systematic review and meta-analysis of 48 epidemiological studies (44 case-control and 4 cohort studies; Hernán et al., 2002) found that current cigarette smokers had a 61% lower risk of PD compared to never smokers (relative risk 0.39, 95% CI 0.32–0.47), and ever smokers had an overall 41% lower risk (relative risk 0.59, 95% CI 0.54–0.63). However, these observational studies evaluated tobacco smoking rather than isolated nicotine intake, and it remains unresolved whether the link represents a true neuroprotective effect of nicotine, non-nicotine constituents of tobacco, or reverse causality (such as premorbid loss of dopamine-driven reward seeking causing individuals to avoid or quit smoking before motor symptoms develop). Moreover, randomized controlled trials evaluating nicotine therapy directly have failed to demonstrate clinical benefit in Parkinson's disease.
- context: A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease… (Annals of neurology 2002) · cited 817x in the literature
"Results for smoking were based on 44 case-control and 4 cohort studies, and for coffee 8 case-control and 5 cohort studies. Compared with never smokers, the relative risk of Parkinson's disease was 0.59 (95% CI, 0.54-0.63) for ever smokers, 0.80 (95% CI, 0.69-0.93) for past smokers, and 0.39 (95% CI, 0.32-0.47) for current smokers." (abstract, results, passage verified)
pubmedfull study (doi) - context: Nicotine Therapy for Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. (Biomedicines 2025) · cited 3x in the literature
"This meta-analysis included five RCTs (346 participants). Nicotine therapy led to no significant improvement in motor outcomes in the short term (pooled SMD: -0.452, 95% confidence interval: -1.612 to 0.708) or long term (pooled SMD: 0.174, 95% confidence interval: -0.438 to 0.787)." (abstract, results, passage verified)
pubmedfull study (doi)
A 2012 study from Baylor College of Medicine found that after 12 weeks of nicotine use, nicotine withdrawal caused a 29% drop in baseline dopamine that persisted for at least 10 days.
"A 2012 study from the Baylor College of Medicine measured what happens to your dopamine when you use nicotine... After 12 weeks of nicotine use, 3 months, withdrawal of nicotine produced a 29% drop in baseline dopamine... And to make matters worse, the deficit in the study persisted for at least 10 days." (said at 0:17:26)
A 2012 study conducted at Baylor College of Medicine (PMID 21872847) demonstrated that withdrawal after 12 weeks of chronic nicotine administration caused a significant reduction in basal dopamine concentrations in the nucleus accumbens that persisted across the 10-day evaluation window. However, this study was conducted in mice using in vivo microdialysis and cyclic voltammetry, not in humans, so direct extrapolation to human dopamine dynamics during nicotine cessation is indirect.
Americans spend between 93% and 96% of their lives indoors.
"93% to 96% of our lives as Americans are spent indoors." (said at 0:07:05)
Large-scale population time-activity surveys indicate that Americans spend the vast majority of their time in enclosed environments, though the 93% to 96% figure typically includes time spent inside vehicles as well as indoor buildings. In the EPA-sponsored National Human Activity Pattern Survey (NHAPS) of 9,386 respondents across the contiguous United States, Americans were found to spend an average of approximately 87% of their time in indoor locations (such as residences, workplaces, stores, and schools) and an additional 6% inside vehicles, totaling about 93% of time in enclosed microenvironments and only 6–7% outdoors. Related North American human activity surveys (such as CHAPS) report very similar figures, with ~89% spent indoors and ~5% in vehicles.
A 2022 study of UN and FAO data across 175 countries found a positive correlation between red meat intake and longevity that remained significant after adjusting for GDP and education level.
"In 2022, a study was published looking at UN and FAO data across 175 countries that found a positive correlation between red meat intake and longevity. That means the people that ate the most red meat lived longest. Yeah, you never heard about that one on the evening news, did you? And that positive correlation held up after adjustment for the gross domestic product of those countries and education level." (said at 0:08:10)
A 2022 cross-sectional ecological study by You et al. published in the *International Journal of General Medicine* analyzed UN and FAO data from 175 contemporary populations. The study did report a statistically significant positive correlation between total meat consumption and life expectancy at birth and at 5 years of age, which remained significant after adjusting for GDP/urbanization, caloric intake, obesity, and education level. However, the study evaluated *total meat intake* (not specifically red meat), and as an ecological (population-level) study, it cannot demonstrate that individual meat consumption causes longer life or that people who eat the most red meat live longest.
A 2025 trial in Neurotherapeutics found that carnosine supplementation directly improved cognitive outcomes.
"In a 2025 trial in the Neurotherapeutics, carnosine supplementation directly improved cognitive effects. So, carnosine can be beneficial for your brain." (said at 0:19:10)
A 2025 randomized, placebo-controlled trial published in Neurotherapeutics evaluated the effect of daily carnosine supplementation (2 g daily for up to 12 weeks) on cognitive performance. However, significant improvements in overall cognitive speed and efficiency were found selectively in the youngest age group (23–35 years) as a post-hoc secondary analysis. Older age groups (36–50 and 51–65 years) demonstrated few or no significant improvements, meaning the cognitive benefits cannot be generalized across all ages.
The human body requires more than 10 grams of glycine per day but can synthesize only about 3 grams per day, resulting in a 7 to 10 gram daily glycine deficit.
"The human body probably needs an excess of 10 g of glycine per day, but your body can only make 3 g a day. Glycine is not considered an essential nutrient, but it should be. And most of us have a 7 to 10-plus gram glycine gap." (said at 0:20:21)
The speaker's figures directly mirror a published theoretical metabolic flux model by Meléndez-Hevia et al. (2009). That paper calculated that de novo glycine biosynthesis from serine is constrained to approximately 3 g/day, whereas total metabolic demands (predominantly collagen synthesis) in a 70 kg human require substantially more, creating a theoretical deficit of approximately 10 g/day. However, these figures are based on mathematical and stoichiometric flux calculations rather than experimental human balance trials or established dietary guidelines, which still classify glycine as a conditionally dispensable amino acid.
Collagen's primary molecular structure is a repeating tripeptide sequence composed largely of glycine, proline, and 4-hydroxyproline.
"What is collagen? It's essentially a three amino acid repeating sequence with some variation that's small. Glycine, proline, 4-hydroxyproline." (said at 0:21:45)
Collagen is defined structurally by a repeating (Gly-X-Y)n tripeptide pattern in which glycine is strictly required at every third position, while proline and 4-hydroxyproline are the most frequent amino acids occupying the X and Y positions. Glycine, proline, and 4-hydroxyproline together constitute a major fraction of collagen's amino acid composition, and Gly-Pro-Hyp is considered the prototypical triplet motif. However, the X and Y positions vary considerably across the protein chain, accommodating various other nonpolar and charged amino acids rather than consisting exclusively of proline and 4-hydroxyproline.
A 2025 cohort study of over 130,000 people showed that low lean muscle mass was a strong predictor of increased mortality.
"Studies like this one from 2025 showed that in large cohorts, in this case over 130,000 people, not having enough lean muscle mass was a strong predictor of increased mortality." (said at 0:23:00)
Large-scale prospective cohort studies and meta-analyses consistently find that low lean muscle mass (or low fat-free mass) is a significant independent predictor of increased all-cause mortality in adult populations. For instance, a comprehensive systematic review and meta-analysis of prospective cohort studies comprising over 1.1 million participants found that low fat-free mass was associated with a 42% higher risk of all-cause mortality (RR: 1.42, 95% CI: 1.30–1.55). While observational evidence strongly links lower lean mass to higher mortality across various measurement modalities (such as DXA, CT, and bioelectrical impedance), these data represent observational associations and may be influenced by reverse causality, underlying disease, or frailty.
- supports: Long-term impact of sarcopenia on functional decline and mortality in community-dwelling o… (Frontiers in nutrition 2025) · cited 4x in the literature
"A total of 39 studies involving 76151 participants were included. Sarcopenia was significantly associated with an increased risk of all-cause mortality (29 publications, OR = 1.79, 95%CI: 1.55~2.06) and functional decline (16 publications, OR = 1.90, 95%CI: 1.55~2.32)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Association Between Fat-Free Mass and Mortality: A Systematic Review and Meta-Analysis. (Journal of cachexia, sarcopenia and muscle 2026)
"Of 7741 screened records, 49 studies met the inclusion criteria (1 149 807 participants; 83 798 deaths). Low versus high fat-free mass was associated with higher all-cause mortality (RR: 1.42, 95% CI: 1.30-1.55)." (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 2.5 to 3 grams of the amino acid leucine is required per meal to trigger muscle protein synthesis.
"How much leucine? Well, you need about 2.5 to 3 g of leucine to get enough of this amino acid to trigger muscle protein synthesis." (said at 0:24:26)
The figure of approximately 2.5 to 3 grams of leucine per meal is widely cited in sports nutrition and metabolic research based on the 'leucine trigger' and 'leucine threshold' hypotheses, which represent the intake typically considered necessary to maximally stimulate (saturate) muscle protein synthesis (MPS) via mTORC1 signaling, corresponding to roughly 20 to 30 grams of high-quality intact protein (such as whey). However, claiming that 2.5 to 3 g is strictly required to 'trigger' MPS requires qualification: lower doses (e.g., 1 to 2 g) can stimulate MPS in young, healthy, or exercised individuals, whereas higher doses (2.5 to 3+ g) are primarily needed to overcome age-related anabolic resistance in older adults. Furthermore, recent systematic reviews note that while the leucine trigger applies well to isolated proteins and older adults, MPS regulation in whole-food mixed meals is more complex than a simple leucine threshold.
- supports: Protein metabolic roles in treatment of obesity. (Current opinion in clinical nutrition and metabolic care 2010) · cited 48x in the literature
"New molecular mechanisms have defined the benefits of protein as a meal threshold for the branched-chain amino acid leucine, which has been characterized as a unique signal regulator of muscle protein synthesis. Leucine consumed at 2.5 g triggers a postmeal anabolic response that protects metabolic active tissues during weight loss and increases loss of body fat." (abstract, results, passage verified)
pubmedfull study (doi) - context: Evaluating the Leucine Trigger Hypothesis to Explain the Post-prandial Regulation of Muscl… (Frontiers in nutrition 2021) · cited 73x in the literature
"This systematic review underscores the merits of the leucine trigger hypothesis for the explanation of the regulation of MPS. However, our data indicate that the leucine trigger hypothesis confers most application in regulating the post-prandial response of MPS to ingested proteins in older adults. Consistent with our hypothesis, we provide data to support the idea that the leucine trigger hypothesis is more relevant within the context of ingesting isolated protein sources rather than protein-rich whole foods." (abstract, conclusion, passage verified)
pubmedfull study (doi) - context: Association of postprandial postexercise muscle protein synthesis rates with dietary leuci… (Physiological reports 2023) · cited 40x in the literature
"Dietary protein ingestion augments post (resistance) exercise muscle protein synthesis (MPS) rates. It is thought that the dose of leucine ingested within the protein (leucine threshold hypothesis) and the subsequent plasma leucine variables (leucine trigger hypothesis; peak magnitude, rate of rise, and total availability) determine the magnitude of the postprandial postexercise MPS response... Ingested leucine dose was associated with the magnitude of the MPS response in older, but not younger, adults over acute (0-2 h, r 2 = 0.64, p = 0.02) and the entire postprandial (>2 h, r 2 = 0.18, p = 0.01) period." (abstract, results, passage verified)
pubmedfull study (doi)
Fact-checked episodes
Publications
No PubMed publication profile has been built for this speaker yet.